◈ Nootpedia
Compact view
Research pass: medium Compound WATCH-LIST LOW

Sunifiram

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict WATCH-LIST LOW

Striking rodent potency story but zero modern human trials, no GMP supply, and reports of seizures/headaches at higher doses. The mechanism overlap with TAK-653 makes the clinical-stage compound the safer way to chase the same effect. Would upgrade to OPTIONAL-ADD only if (a) a human dose-finding trial appears, (b) a vendor with verified COAs emerges, and (c) the seizure question is resolved.

Research pass: medium
▸ Decision matrix by user profile Per-archetype
  • Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype)
    WATCH-LIST

    low. Mechanistically interesting but TAK-653 is the better-developed cousin. Skip until a human dose-finding study lands.

  • 30-50, executive maintenance
    WATCH-LIST

    low. Same reasoning.

  • 50+, mild cognitive decline
    SKIP-FOR-NOW

    Established AMPA-PAM clinical candidates dominate this niche.

  • Anxiety-prone
    SKIP

    pro-glutamatergic stimulation reportedly worsens anxiety in a meaningful subset.

  • High athletic load, tested status
    SKIP

    undefined banned-substance status.

  • Sleep-disordered
    SKIP

    daytime only at best; seizure threshold concern compounds with sleep deprivation.

  • Recovery-focused
    SKIP

    no relevant evidence.

  • Strength/anabolic-focused
    I
▸ Subjective experience (deep)

Per forum reports (low confidence, no purity standardization):

  • Onset 20-60 min oral or sublingual
  • Verbal fluency, word-finding, "ideas come faster"
  • Mild stimulation without classic stimulant body load
  • Some users report music appreciation increase (consistent with mild AMPA-PAM signature)
  • Duration 3-6 hours
  • Headache, irritability, and occasional anxiety with daily or high-dose use
  • A small but recurring fraction of reports describe "felt like a seizure was coming on" or pronounced muscle twitching at >20 mg — credibility unclear, but mechanistically plausible
▸ Tolerance + cycling deep dive
  • Tolerance buildup: Likely fast based on glutamatergic mechanism and forum reports of diminishing effect within 1-2 weeks of daily use.
  • Recommended cycle: Forum convention is 1-3× per week with multi-day breaks.
  • Reset protocol if needed: Unknown.
▸ Stacking deep dive

Synergistic with

  • Cholinergic precursors (alpha-GPC, citicoline): Forum-popular pairing — AMPA potentiation increases ACh demand, so a cholinergic floor reduces headache risk.
  • Aniracetam: Theoretically additive AMPA potentiation; risk = compounded seizure threshold reduction.

Avoid stacking with

  • Other ampakines, IDRA-21, TAK-653: Additive AMPA modulation = additive seizure risk.
  • Bupropion, tramadol, high-dose modafinil: Independent seizure liability.
  • Sleep deprivation: Lowers seizure threshold.

Neutral / safe co-administration

Generally unstudied. Common forum stack: + alpha-GPC + caffeine + theanine.

▸ Drug interactions deep dive

None characterized in humans. CYP profile not published. No drug-drug interaction studies exist.

▸ Pharmacogenomics

Unknown. No human PG data.

▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
Research chemical Various RC vendors $20-60 / gram Low-medium Some vendors provide COA; potency variable; not for human consumption per vendor disclaimers
▸ Biomarkers to track (deep)
  • N/A — not recommended for use. If used despite recommendation, baseline seizure history and EEG would be the minimum.
▸ Controversies / open debates Live debate
  • The Italian academic group that produced sunifiram (Ghelardini, Romanelli) published a detailed mechanism story but never advanced it to human trials. Why is unclear — likely a combination of seizure liability, IP/funding constraints, and the broader collapse of cognitive-enhancement drug development at that time.
  • Forum users tend to rank sunifiram > unifiram > IDRA-21 in subjective potency, but with no purity controls and no objective testing this ranking is essentially folklore.
  • A 2014 brief case discussion (Stout & Cimino) flagged adverse events in self-experimenting users including anxiety and sleep disturbance — small N but consistent with the forum signal.
▸ Verdict change log
  • 2026-05-06 — Initial verdict: WATCH-LIST low confidence. TAK-653 is the cleaner way to chase the same mechanism.
▸ Open questions / gaps Open
  • Zero human PK, zero Phase 1 — entire pharmacology in humans is forum-derived.
  • The "1000× more potent than piracetam" claim is rodent-passive-avoidance-specific and may not translate.
  • Seizure liability in humans is the open question that would actually matter.
▸ Sources (full, with our context)
Back to compact view